Latest news with #1stAnnualRoyaltyCompanyVirtualConference
Yahoo
07-05-2025
- Business
- Yahoo
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference
Fortress Biotech, Inc. MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ('Fortress'), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following sessions at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference, taking place on Tuesday, May 13, 2025: 2:00 p.m. – 2:30 p.m. ET: Fireside Chat 5:00 p.m. – 6:00 p.m. ET: Panel Presentation: Development Stage Companies – Where Do Royalty and Tech Platform Plays Fit? To register for the conference, visit About Fortress Biotech Fortress Biotech, Inc. ('Fortress') is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has eight marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress' portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress' model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children's Hospital and Sentynl. For more information, visit Company Contact: Jaclyn Jaffe Fortress Biotech, Inc. (781) 652-4500 ir@ Media Relations Contact: Tony Plohoros 6 Degrees (908) 591-2839 tplohoros@
Yahoo
07-05-2025
- Business
- Yahoo
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
XOMA Royalty Corporation EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025. Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET. Mr. Hughes will join the 'Pros and Cons of Royalty Model – Especially in Current Financing Environment' panel discussion at 4:00 PM ET. Mr. Sitko will participate in the 'Development-Stage Companies – Where do Royalty and Tech Platforms Play Fit?' panel at 5:00 PM ET. Registration for the conference can be accessed by visiting XOMA Royalty's presentations can be accessed by visiting the investor relations section of the Company's website at In addition, members of XOMA Royalty's business development team will attend the H.C. Wainwright 3rd Annual BioConnect Investor Conference being held on May 20, 2025, in New York, NY. About XOMA Royalty Corporation XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit or follow XOMA Royalty Corporation on LinkedIn. XOMA Investor Contact Juliane Snowden XOMA Royalty +1 646-438-9754 XOMA Media Contact Kathy Vincent KV Consulting & Management kathy@
